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ABSTRACT 
Positron emission tomography (PET) is a powerful analytical tool for the in vivo molecular 
imaging of the human brain. Over the past years, a number of PET studies imaging the 
serotonin transporter (SERT) have been employed, and provided evidence for the key role of 
serotonergic pathology in patients with Parkinson’s disease (PD). Here, we review the role of 
SERT in the development of motor and non-motor complications in patients with PD, and we 
performed a meta-analysis to identify the patterns of SERT pathology and the relevance to 
symptoms. Consistent SERT pathology in raphe nuclei, striatum, thalamus and hypothalamus 
and associations with ageing, PD progression, development of dyskinesias, and cognitive 
decline were observed. 
 
Key-words: PET; DASB; Parkinson’s disease 
Domain: Neuroscience   
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INTRODUCTION 
Serotonergic dysfunction occurs early in the course of Parkinson’s disease (PD)1 and is 
characterized by the presence of Lewy bodies in raphe nuclei2 and by loss of terminals in 
serotonin-containing neurons.3 According to Braak’s staging of PD, the pathological 
processes in serotonergic median raphe nuclei occur in Stage 2, which is a presymptomatic 
stage preceding the lesions of dopaminergic midbrain neurons.2 Biochemical and post-
mortem studies have also confirmed that the serotonergic system is affected in PD.4–6  
 
Positron emission tomography (PET) is a powerful in vivo technique that has been employed 
for the quantification of serotonin pathology in vivo in patients with PD.7,8 This molecular 
imaging technique allows to measure in vivo metabolic processes and aid in the 
understanding of aetiology and pathophysiology of diseases, and in the identification of novel 
pharmacological targets. Several PET ligand have been developed for the evaluation of 
serotonergic receptors and SERT.9 [11C]-3-Amino-4-(2-
dimethylaminomethylphenylsulfaryl)-benzonitrile ([11C]DASB) is a second generation PET 
ligand with high selectivity for the SERT,9 which is superior compared to first generation 
ligands.10 Over the past years, a number of PET studies imaging the SERT have been 
employed, and provided evidence for the key role of serotonergic pathology in patients with 
PD.3,4 
 
The aims of this study are to systematically review the role of SERT in the development of 
motor and non-motor symptoms in PD and to examine in vivo SERT changes in PD patients 
compared to healthy controls (HCs) as measured by [11C]DASB PET by conducting a meta-
analysis for identifying patterns of SERT pathology and the relevance to symptoms. 
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METHODS 
The study was designed according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines (PRISMA) and according to the recommendations from the 
Cochrane Collaboration and Meta-Analysis Of Observational Studies in Epidemiology 
(MOOSE)11 using a methodology as previously described.12,13 
 
Search Strategy 
MEDLINE, ISI Web of Science, Cochrane Library and Scopus electronic databases were 
searched for articles in English published before 1st October 2016. Studies were identified, 
combining the following major Medical Subject Headings: “Parkinson’s disease” and “PET” 
combined with text and key words. Additional eligible studies were identified screening the 
reference lists of studies included in our analysis. 
 
Specific aims for Meta-Analyses 
The current study aims to systematically examine the consistency of in vivo SERT changes in 
PD vs HCs as measured by [11C]DASB PET imaging studies. The primary outcome was the 
mean difference of [11C]DASB binding in striatal and extra-striatal brain areas between PD 
patients and HCs and in relation to the duration and stage of the disease. The secondary 
outcome was to explore the pattern of [11C]DASB binding according to motor and non-motor 
symptoms profile.  
 
Selection Criteria 
All selected titles and abstracts were independently reviewed by two investigators (GP, FN). 
Studies were excluded if the title and/or abstract were not appropriate for the aim of the 
review. Full texts were subsequently obtained for eligible studies or when the relevance of an 
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article could not be certainty excluded. Selected studies were eligible if they met the 
following criteria: (a) cross-sectional, case control or longitudinal [11C]DASB PET studies 
including PD patients with confirmed diagnosis based on the UK brain bank criteria, (b) 
studies published in peer-reviewed journals, (c) [11C]DASB PET measures reported as mean 
± standard deviation (SD), and (d) Studies not including HCs were included in the meta-
analysis only for secondary analyses within PD subgroups. In cases of two or more studies 
from the same centre, we have carefully checked for overlapping samples by contacting the 
corresponding authors to verify that there was not a significant overlap in the samples. For 
studies including overlapping PD samples, we have included only the study with the largest 
sample in the meta-analysis. 
 
Risk of bias in included studies 
The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS)14 
that includes selection, comparability, and exposure (case-control studies) or outcome (cohort 
studies). The scale ranged from zero to six stars with the highest degree representing the 
greatest methodological quality. Disagreement was resolved by consensus and by opinion of 
a third reviewer (MP). The presence of publication bias was explored by performing the test 
for asymmetry of the funnel plot by Egger.15 
 
Data extraction  
Two reviewers (GP, FN) independently completed the data extraction and variables extracted 
were study year, author first name, gender, mean age of participants, number of participants, 
disease duration (years), Hoehn and Yahr (H&Y) scale, Unified Parkinson's Disease Rating 
Scale (UPDRS) total score and UPDRS Part-III motor score, MMSE and [11C]DASB binding 
data. 
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Statistical Analysis 
Data were analysed using the Comprehensive Meta-Analysis software, version 3 (Biostat, 
Englewood, NJ, USA). Considering we have included studies using only [11C]DASB PET, 
comparisons between patients with PD and HCs and those within PD patients have been 
calculated as difference in means (MD). A negative MD indicates a decreased [11C]DASB 
binding in PD patients compared to HCs. The results were pooled using the inverse variance 
method. Heterogeneity was assessed using the I2 index statistic, which accounts for between-
study (or inter-study) variability as opposed to within-study (or intra-study) variability. 
Heterogeneity was considered substantial if the I2 value was greater than 40%.16 Due to the 
heterogeneity of samples, a random effect model was used to summarise data instead of a 
fixed effect model, independently of statistical evidence for heterogeneity.17 
 
To investigate the impact of individual studies on the results, we undertook one study-
removed analysis by omitting one study in each turn and recalculating the pooled estimates 
on remaining studies.18 To explore the influence of potential effect modifiers on [11C]DASB 
binding, meta-regression analyses were performed to test age, gender (male %), disease 
duration, H&Y scale, UPDRS total score and UPDRS Part-III motor score, MMSE and 
quality of the study (NOS), when at least 10 studies were available for each modifier. For all 
meta-regression analyses, a random effect model was used to take into account the mean of a 
distribution of effects across studies. To estimate the additive (between-study) component of 
variance τ2, the restricted maximum likelihood method was used to take into account the 
occurrence of residual heterogeneity, not explained by the potential effect modifiers.19 All 
reported test results were two-tailed and statistical significance was set at a P<0.05. 
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SYSTEMATIC REVIEW 
SERT pathology in PD 
Over the past years [11C]DASB PET studies have demonstrated SERT changes in patients 
with PD,1,20-22, Staging of  SERT dysfunction in PD patients has shown reductions of 
[11C]DASB binding in the caudate, thalamus, hypothalamus, and anterior cingulate cortex in 
early PD patients followed by additional [11C]DASB binding reductions in the putamen, 
insula, posterior cingulate cortex, and prefrontal cortex in patients with established PD. 
Advanced PD patients showed further [11C]DASB binding reductions in the ventral striatum, 
raphe nuclei and amygdala.1  
 
Other studies have reported modest widespread reductions of [11C]DASB binding in caudate, 
putamen, midbrain and orbitofrontal cortex in advanced PD patients compared to controls.20 
[11C]DASB binding in early PD patients has been reported both reduced1,21 and within 
normal levels.22 In Strecker and colleagues study,22 however, only nine de novo non-
demented and non-depressed PD patients were compared to nine controls, and the small 
sample size may explain the lack of statistical significance.  
 
Motor symptoms and complications 
Serotonergic pathology has been associated with the development of motor symptoms23,24 
and complications.25–30 The development of tremor in PD has been speculated to be 
underlined by non-dopaminergic mechanisms due to the fluctuating response of this symptom 
to dopaminergic supplementation and the lack of correlations with dopaminergic molecular 
imaging markers.31-33 [11C]DASB PET studies have shown reduced SERT binding in the 
caudate, putamen, raphe nuclei and thalamus of tremor-dominant PD patients with compared 
with those who had akinetic-rigid phenotype. Moreover, caudate, putamen and raphe nuclei 
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SERT levels correlated with postural and action tremor.23 These findings complement earlier 
results which demonstrated a correlation between reduced raphe 5-HT1A binding and severity 
of resting tremor in patients with PD.24  
 
The role of serotonergic mechanisms in the development of levodopa-induced dyskinesias 
(LIDs) in PD patient have been evaluated in four PET studies.25-28 First, by using [11C]DASB 
and [11C]raclopride (to evaluate striatal dopamine release) PET imaging, we found a relative 
preservation of SERT binding in putamen in PD patients with LIDs and demonstrated that 
identical levodopa doses induced markedly higher striatal synaptic dopamine concentrations 
in PD patients with LIDs compared with PD patients with stable responses to levodopa. 
Moreover, oral administration of the serotonin receptor type 1A agonist buspirone prior to 
levodopa reduced levodopa-evoked striatal synaptic dopamine increases and attenuated 
LIDs.25 
 
Lee and colleagues26 found no difference in striatal dopaminergic pathology (assessed by 
[18F]FP-CIT PET) between dyskinetic and non-dyskinetic PD patients, however, [11C]DASB 
to [18F]FP-CIT binding ratio (indicating serotoninergic to dopaminergic terminal availability) 
was highest in the putamen of PD patients with LIDs. These findings were confirmed later by 
Roussakis et colleagues27 which demonstrated that SERT to DAT ratio increases as PD 
progresses and patients experience LIDs. Overall these findings suggest that when the 
dopaminergic innervation in the striatum is critically low, the serotonergic system plays an 
important role in development of LIDs. Smith et colleagues28 used [11C]DASB PET and 
found relative preservation of SERT binding in the globus pallidus in PD patients with LIDs 
that was associated with a significant rise in pallidal synaptic dopamine levels, detected by 
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[11C]raclopride PET, and suggesting that pallidal serotonergic terminals are also important in 
the development of LIDs in PD.  
 
Serotonergic mechanisms such as excessive striatal innervation and high serotonin to 
dopamine striatal terminal ratio have been also associated with the development of graft-
induced dyskinesias in PD patients who underwent striatal transplantation with foetal ventral 
mesencephalic tissue.29,30  
Non-motor symptoms 
The pathophysiology of non-motor symptoms in PD remains unclear, and serotonergic 
pathology has been hypothesized as one of the main mechanisms underlying depression,22,34-
36 fatigue,37 apathy,38,39 weight changes,40 sleep problems,41,42 olfactory dysfunction43 and 
visual hallucinations in PD.44 An [11C]DASB PET study in transplanted PD patients with 
dopamine-rich foetal ventral mesencephalic tissue and successful dopaminergic reinnervation 
has shown widespread progressive decline of SERT binding up to three decades following 
diagnosis that could be associated with the development of non-motor symptoms in PD.45  
 
We have found three studies investigating SERT levels in PD depression22,34,35. In two of 
them34,35 an increase of SERT binding in limbic structures34 and in raphe nuclei35 was found 
in depressed compared with non-depressed PD patients. Higher SERT levels were correlated 
with worse depressive symptoms as assessed by Hamilton Depression Rating Scale,34,35 or 
Beck Depression Inventory-II.35 A third study22 found no correlation between depression and 
SERT levels in PD. However, this study was not conducted on PD patients with a clinical 
diagnosis of depression. The prevalence of depression in PD is higher than general 
population. This might due to the combination of SERT upregulation, which is typical of 
depression, and loss of serotonergic terminals, which is typical of PD.  
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We found only one study investigating the relationship between SERT and fatigue.37 
Compared to the PD patients without fatigue, PD patients with fatigue showed about 75% 
[11C]DASB binding reduction in putamen, caudate, ventral striatum, thalamus, cingulate and 
amygdala. SERT dysfunction has also been associated to apathy in one recent study.38 They 
used [11C]DASB and [11C]PE2I PET to index presynaptic serotonergic and dopaminergic 
function, respectively, in fifteen apathetic and fifteen non-apathetic untreated patients with 
Parkinson’s disease. Their findings demonstrate greater serotonergic loss in the basal ganglia 
in apathetic patients with Parkinson’s disease compared to patients without apathy, while 
both Parkinson’s disease groups showed reduced dopaminergic uptake compared to controls. 
Moreover, greater serotonergic loss in caudate and orbitofrontal cortex correlated with the 
severity of apathy in patients with Parkinson’s disease, whereas apathy was not associated 
with dopaminergic deficits.39 One [11C]DASB PET investigated the link between SERT 
dysfunction and body mass index (BMI).40 PD patients with abnormal BMI changes over a 
12-month period showed significantly increases of [11C]DASB binding in rostral raphe 
nuclei, hypothalamus, caudate nucleus and ventral striatum compared to subjects with no 
significant BMI changes.  
 
Only few human studies have been conducted investigating the role of SERT pathology in the 
development of sleep problems in PD.41,42 Kotagal et colleagues41 found no differences in 
brainstem and striatal [11C]DASB binding between PD patients with and without RBD. 
Lelieveld and colleagues42 found decreased [11C]DASB binding in the brainstem of PD 
patients with sleep-disordered breathing that was not associated with the severity of sleep-
disordered breathing.  
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Olfactory dysfunction can precede the motor onset of PD symptoms by many years.46 Only 
one study investigated the association between smell problems and SERT dysfunction43. 
They found no significant correlations between UPSIT scores and [11C]DASB binding within 
raphe nucleus, amygdala, hippocampus, striatum, or neocortex. This finding suggests no 
major role of SERT damage in the deficit of odor identification in PD.  
 
No studies have investigated SERT binding and visual hallucinations using [11C]DASB PET. 
However, a study using [18F]setoperone PET imaging in PD patients showed that visual 
hallucinations were associated with increased 5-HT2A binding in ventral visual pathway,  
dorsolateral prefrontal cortex, medial orbitofrontal cortex, and insula.44 These findings 
suggested that abnormalities in serotonin neurotransmission could be involved in the neural 
mechanisms underlying the development of visual hallucinations that are associated with PD, 
and support the use of selective 5-HT2A receptor antagonists for their treatment.44  
  
RESULTS OF META-ANALYSIS 
Of 6380 articles identified by the initial search, 49 were retrieved for more detailed 
evaluation. We then excluded 29 PET and SPECT studies which used ligands with no 
specific SERT binding. Finally, 20 [11C]DASB PET studies were included in the meta-
analysis.1,20–23,25–30,34,35,37,40–42,45,47,48 The study cohorts in this meta-analysis included 234 PD 
patients and 225 HCs (Table 1). The quality of included studies was moderate or good, 
varying from four to six NOS stars (Table 2).  
 
Primary outcome: [11C]DASB binding in PD patients compared to HCs and in relation to 
the duration and stage of the disease 
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PD patients showed a significant reduction of [11C]DASB binding compared to HCs  in 
rostral raphe, caudal raphe, putamen, caudate, ventral striatum, thalamus and hypothalamus 
(Figure 1). 
 
In presence of relevant heterogeneity (I2>40%) and where more than 10 [11C]DASB studies 
were included in the analysis, a meta-regression was carried out for the primary outcome of 
[11C]DASB binding in putamen, caudate, ventral striatum, thalamus and hypothalamus 
(Figure 2). Longer disease duration was correlated with decreased [11C]DASB binding within 
putamen (Figure 2A; n of studies=19, β=–0.0204, change of τ2=0.0277, 95% CI=–0.0339 to –
0.0069, P=0.0031; r2=0.95). Older age and lower MMSE but not disease duration was 
correlated with decreased [11C]DASB binding in caudate (Figure 2B; n of studies=19, change 
of τ2=0.0192; Age: β=–0.0258, 95% CI=–0.0469 to –0.0048, P=0.0163; MMSE: β=0.1193, 
95% CI=0.0154 to 0.2233, P=0.0244; r2=0.56). Decreased [11C]DASB binding in ventral 
striatum was not correlated with disease duration or with any other potential modifiers. 
Decreased [11C]DASB binding in thalamus was correlated with longer disease duration (n of 
studies=17, β=–0.0156, change of τ2=0.0311, 95% CI=–0.0246 to –0.0067, P=0.0006; 
r2=0.94) and H&Y stage (n of studies=13, β=–0.1243, change of τ2=0.0.0021, 95% CI=–
0.2043 to –0.0443, P=0.0023; r2=1.00) at univariate analysis. However, at multivariate meta-
regression including disease duration and H&Y stage, there were no correlations. Decreased 
[11C]DASB binding within hypothalamus was not correlated with disease duration but with 
male gender (n of studies=12, change of τ2=0.0163; β=–0.0073, 95% CI=–0.0128 to –0.0018, 
P=0.0093; r2=1.0). 
 
Secondary outcomes: [11C]DASB binding within PD subgroups according to motor and 
non-motor symptoms 
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[11C]DASB binding between dyskinetic PD vs non-dyskinetic PD patients showed no 
differences in putamen (n of studies=3, PD patients with dyskinesia=51, PD patients without 
dyskinesia=33; MD=−0.106, 95% CI=−0.284 to 0.072, P=0.243; I2=71.3%) and globus 
pallidus (n of studies=2, PD patients with dyskinesia=22, PD patients without dyskinesia=22; 
MD=−0.091, 95% CI=−0.147 to 0.328, P=0.455; I2=83.9%). Caudate [11C]DASB binding 
was reduced in PD dyskinetic compared to non-dyskinetic PD patients (n of studies=3, PD 
patients with dyskinesia=51, PD patients without dyskinesia=33; MD=−0.178, 95% 
CI=−0.294 to –0.062, P=0.003; I2=46.4%).  
 
We found only one study investigating [11C]DASB binding in PD patients with and without 
tremor,23 thus no meta-analysis has been performed for this outcome. Three studies 
investigated the association between [11C]DASB binding and depression levels in PD.22,34,35 
However, no meta-analysis has been performed for this outcome because two studies did not 
report [11C]DASB binding in PD without depression.34,35 Only one study was found 
investigating [11C]DASB binding in PD patients with and without fatigue,37 one in PD 
patients with rapid eye movement sleep behavior disorder,41 and one with sleep-disordered 
breathing42 thus, no meta-analyses have been performed for these outcomes.  
 
Publication Bias and Sensitivity Analysis 
For the primary outcome, the Egger test was not significant in any of the brain areas, with the 
exception of ventral striatum (P=0.011), indicating a risk of publication bias only for this 
area. Robustness of meta-analytic findings was confirmed by sequentially removing each 
study and re-analysing the remaining data set (producing a new analysis for each study 
removed). The results remained unchanged regarding direction and magnitude (data not 
shown). Meta-regression revealed no significant effect of the quality of the studies (NOS 
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scores) on [11C]DASB binding in any brain area, with the exception of hypothalamus (n of 
studies=12, β=0.2145, change of τ2=0.0163, 95% CI=0.0369 to 0.3922, P=0.0018; r2=0.39) in 
which lower study quality was associated with lower [11C]DASB binding. 
 
DISCUSSION 
To the best of our knowledge, this is the first comprehensive systematic review and meta-
analysis investigating SERT changes in PD. Compared to HCs, [11C]DASB binding has been 
generally reported decreased in PD. Only studies in PD depression demonstrated relative 
increased [11C]DASB binding in patients with PD depression compared to non-depressed PD 
patients.34,35 [11C]DASB binding in early PD patients has been reported either reduced1,21 or 
within normal levels.22  
 
With regards to motor symptoms, we found in our systematic review that SERT dysfunction 
is associated with the development of tremor and dyskinesias in PD. With regards to non-
motor symptoms, we found in our systematic review that SERT dysfunction is associated 
with depression, fatigue, apathy and weight changes. Associations with sleep problems and 
olfactory dysfunction need further investigations while visual hallucinations seems to be 
related with impairment of serotonergic receptors more than SERT levels. However, due to 
the small number of studies and relatively small sample sizes, the conclusions regarding the 
relationship between serotonergic dysfunction and clinical features of PD need further 
evaluations. 
 
Our meta-analysis demonstrates that SERT binding is reduced in patients with PD in rostral 
and caudal raphe, putamen, caudate, ventral striatum, thalamus and hypothalamus. Reduced 
SERT binding in putamen is associated with longer duration of the disease. PD patients with 
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dyskinesias showed preserved SERT binding in putamen compared to non-dyskinetic PD 
patients. Lower [11C]DASB binding in caudate is associated with worse cognitive function 
and older age. 
 
The widespread decrease of SERT binding in patients with PD confirms the important role of 
serotonergic system dysfunction in the pathophysiology of PD. The highest decreases in 
SERT binding were observed in the rostral raphe and caudate followed by putamen, 
thalamus, ventral striatum, caudal raphe, and hypothalamus. According to Braak’s staging, 
raphe nuclei are one of the first brain regions affected by Lewy body and neurite deposition 
and could be preceding dopaminergic pathology and the development of motor symptoms.2 
Later stages involve pathology in the hypothalamus, the striatum and the thalamus. Also, 
previous molecular imaging and post-mortem studies have reported a preferential loss of 
SERT binding in the caudate compared to the putamen.1,4,6 Our meta-analytical findings are 
in line with these observations.  
 
Our findings demonstrate that loss of SERT binding in caudate and putamen have important 
clinical relevance. The risk of cognitive impairment increases with ageing and our findings 
show that SERT binding in caudate is reduced with advanced age and is associated with 
worse cognitive scores. Several pathological processes have been implicated in the 
development of cognitive impairment in PD and these include degeneration of subcortical 
cholinergic and dopaminergic projections, microglial activation, and neocortical pathology 
associated with misfolded protein depositions or vascular pathology.49 A recent study has 
demonstrated that the combined presence of striatal and cortical β-amyloidopathy is 
associated with greater cognitive impairment than cortical β-amyloidopathy alone in PD,50 
indicating an important role of striatal β-amyloid pathology in the development of cognitive 
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impairment in PD. Additional studies have shown that β-amyloid levels could affect 
serotonin signalling51,52 and that striatal serotoninergic degeneration may promote the 
development of cerebral amyloidopathy in patients with PD.48 
 
Our findings confirm that SERT binding in putamen plays a crucial role in the 
pathophysiology of dyskinesias in patients with PD. Our data show relative preservation of 
SERT binding within putamen in dyskinetic PD compared to non-dyskinetic PD patients. 
Previous experimental studies have demonstrated that abnormal involuntary movements in 
rats are critically dependent on the integrity of serotonergic projections and that removal of 
striatal serotonergic afferents or the dampening serotonergic activity with serotonin receptor 
agonists attenuated abnormal involuntary movements.53–55 Clinical and molecular imaging 
studies in humans have shown that striatal serotonergic terminals contribute to the abnormal 
levodopa- or graft-induced increases in synaptic dopamine levels in PD patients and in the 
development of dyskinesias.25–30,56 Although SERT binding in putamen decreases with 
advanced disease, it remains unclear why PD patients with dyskinesias have relatively 
preserved putaminal serotonergic function. It is possible that SERT upregulation or 
interactions with other systems may play a role. Future studies will be needed to elucidate 
this mechanism.   
 
In this meta-analysis, data showed that reduced SERT binding in the hypothalamus was 
associated with male gender. Previous studies on gender differences in PD have shown a 
more benign phenotype in women with PD, which could be the result of higher physiological 
striatal dopamine levels, possibly due to the activity of oestrogens.57 Oestrogens also regulate 
gene expression of serotonin in midbrain and hypothalamus and their effect in SERT binding 
cannot be excluded.58 
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The main strength of our meta-analysis was the systematic strategy and the inclusion of PET 
studies with high selectivity for SERT. The main limitations are that the meta-analysis was 
not carried out on individual patient data stratified for different PD symptoms and was 
limited to non-cortical regions. We have decided to exclude cortical areas due to the lack of 
data and the heterogeneity of reporting results among the studies. Additional limitations 
included the small sample sizes and low quality of some studies that represent a potential risk 
of bias (e.g. for the hypothalamus). Another possible limitation is the presence of publication 
bias for ventral striatum. The risk of bias evidenced by the funnel plot asymmetry needs to be 
interpreted considering the small number of studies included.  
 
Future directions 
Serotonergic pathology plays a key role in the progressive neurodegenerative process in the 
course of PD and PET imaging such as [11C]DASB PET provides the means for direct 
visualisation and quantification in vivo in patients with PD. Although several studies have 
been performed using serotonergic PET ligands, the vast majority of associations between 
serotonergic pathology and PD symptoms requires further validation. Future [11C]DASB PET 
studies in subjects at higher risk for developing PD and in familial forms of PD may shed 
light for the premanifest stages and pathology. Currently all studies have been cross-sectional 
and new longitudinal designs, perhaps employing various PET ligands for the quantification 
of serotonergic markers, are needed to better understand the progression of serotonergic 
pathology and the relation to symptoms and complications in patients with PD.  
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FIGURE LEGENDS 
Figure 1 Pooled analysis for [11C]DASB binding in PD patients compared with HCs. 
PD = Parkinson’s disease; HCs = Healthy controls. 
 
Figure 2 Meta-regression analysis for primary outcome exploring effect modifiers and 
[11C]DASB binding within putamen (A) and caudate (B). Differences in means are displayed 
on a logarithmic scale. Circles represent studies included in the meta-analysis. The size of 
circles represents the weight of each study on the results of the meta-analysis. 
MMSE = Mini-Mental State Examination; PD = Parkinson’s disease; HCs = Healthy 
controls. 
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Table 1 [11C]DASB PET studies included in the meta-analysis. 
Study and Group Age 
(yrs) 
Male 
(%) 
Disease 
duration 
(years) 
H&Y 
stage 
OFF 
MDS-
UPDRS 
total 
OFF 
MDS-
UPDRS 
part 3 
MMSE 
(MoCA) 
PD (n=9)20 65 77.8% 12 2.55 N/A N/A N/A 
PD (n=7)34 61.1 57.1% 3 1.6 21.1* N/A N/A 
PD (n=5)21 64 80% N/A 1.7 N/A N/A N/A 
PD (n=12)29 67.1 83.3% 12.5 N/A N/A N/A 28.5 
PD non-depressed (n=24)35 66.8 83.3% 8.6 2.5 61.2 N/A 28.3 
PD depressed (n=10)35 60.7 60% 10.3 3.1 81.9 N/A 28.9 
PD Early (n=10)1 62.7 80% 3.4 1.9 50.9 N/A 28.8 
PD Established (n=10)1 62.4 80% 7.5 3.4 69.4 N/A 28.2 
PD Advanced (n=10)1 67.2 80% 14.1 3.4 78.7 N/A 27.8 
PD without fatigue (n=8)37 64.3 62.5% 4.25 N/A N/A 33.9 N/A 
PD with fatigue (n=7)37 64.8 62.5% 5.75 N/A N/A 34.1 N/A 
PD Normal BMI (n=17)40 64.1 82.4% 9.6 2.6 63.8 N/A 28.7 
PD Abnormal BMI (n=17)40 65.3 82.4% 8 2.5 63.9 N/A 28.8 
PD (n=12)30 N/A N/A N/A N/A N/A N/A N/A 
PD (n=9)22 59.2 55.6% 2.1 1.7 23.6 15.3 29.2 
PD (n=13)48 68.4 92.3% 4.77 2.65 N/A 33.7 (24.3) 
PD (n=51)42 64 84.3% 6 2.2 32 N/A 29 
PD (n=12)45 62.9 83.3% 8.1 N/A 72.3 43.2 27.8 
PD transplanted (n=3)45 62 100% 28.3 N/A 29.7 12.3 29.3 
PD without RBD (n=24)41 65.3 66.1% 5.8 2.3 N/A 27.6 (26) 
PD with RBD (n=11)41 63.4 92.6% 6.4 2.3 N/A 25.1 (26.3) 
PD (n=18)47 67.8 66.7% 6.2 N/A N/A 32.3 N/A 
PD without tremor (n=12)23 62.8 66.7% 8.1 N/A N/A 39.7 29.6 
PD with tremor (n=12)23 67.5 91.7% 9.4 N/A N/A 39.7 27.8 
PD without dyskinesia (n=12)25 66.6 83.3% 5.6 2.4 N/A 28.5 29 
PD without dyskinesia (n=24)25 65.2 79.2% 11.8 3.2 N/A 42.1 28.7 
PD de novo (n=10)26 61.3 40% 1.1 1.6 34.2 7.3 27.1 
PD without dyskinesia (n=10)26 61.5 30% 7 1.8 33.4 20.4 27.7 
PD with dyskinesia (n=10) 26 63.9 40% 8.2 2.1 51.4 23 27.5 
PD without dyskinesia (n=11)27 69.3 90.9% 7.8 2.3 40.6 26.7 28 
PD with dyskinesia (n=17)27 61.7 52.9% 11.1 2.4 47.8 28.1 28.4 
PD without dyskinesia (n=12)28 65.6 75% 5 2.3 N/A 23.9 29.3 
PD with dyskinesia (n=12)28 65.2 83.3% 12 3.4 N/A 44.7 29.6 
AVERAGE 64.4 715% 7.4 2.3 51.9 28.8 28.4 
HC=healthy controls; PD=Parkinson’s disease; RBD=REM Behaviour Disorder; N/A=Data not available; *ON medication. 
Table 2 Quality score (Newcastle-Ottawa Scale) 
Study Case 
Definition 
Selection 
of 
Control 
Comparable 
PET Method 
Incomplete 
PET data 
Validated 
diagnosis 
of PD^ 
Disease 
characteristic 
Total 
score 
Guttman et al., 200720 * * * * * * 6 
Boileau et al., 200834 X * * * * * 5 
Albin et al., 200821 * * * * * X 5 
Politis et al., 201029 * * * * * * 6 
Politis et al., 201035 * * * * * * 6 
Politis et al., 20101 * * * * * * 6 
Pavese et al., 201037 * * * * * * 6 
Politis et al., 201140 * * * * * * 6 
Politis et al., 201130 * * * * * X 5 
Strecker et al., 201122 * * * * * * 6 
Kotagal et al., 201248 * X * X * * 4 
Lelieveld et al., 201242 * * * X * * 5 
Politis et al., 201245 * * * X * * 5 
Kotagal et al., 201241 * X * X * * 4 
Pavese et al., 201247 * * * X * * 5 
Loane et al., 201323 * * * * * * 6 
Politis et al., 201425 * * * X * * 5 
Lee et al., 201526 * X * * * * 5 
Roussakis et al 201627 * * * * * * 6 
Smith et al., 201528 * * * X * * 5 
^Based on UK Brain Bank criteria. *=1 point; X=0 point. 
